Securities code: 002370 securities abbreviation: Zhejiang Yatai Pharmaceutical Co.Ltd(002370) Announcement No.: 2022-009 bond Code: 128062 bond abbreviation: Asian medicine convertible bond
Zhejiang Yatai Pharmaceutical Co.Ltd(002370)
2021 annual performance forecast
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Expected performance of the current period
1. Performance forecast period: January 1, 2021 to December 31, 2021
2. Expected performance: √ loss turns into profit, rising and falling in the same direction
The current reporting period of the project is the same period of last year
Loss attributable to listed companies: 180 million yuan – 250 million yuan; Profit: 27.275 million yuan; net profit of shareholders
Net profit after deducting non recurring loss: 195 million yuan – 265 million yuan loss: 143.31312 million yuan profit
Basic earnings per share loss: 0.34 yuan / share -0.47 yuan / share profit: 0.05 yuan / share
The operating income is 300 million yuan – 330 million yuan and 514885300 yuan
The operating income after deduction is 300 million yuan – 330 million yuan and 514.7488 million yuan
2、 Communication with accounting firms
The company has made pre communication with the annual audit accounting firm on matters related to the performance forecast, and there is no significant difference between the company and the accounting firm in the performance forecast.
3、 Explanation of performance change reasons
The main reasons for the change of performance in 2021 are: (1) the reduction of sales revenue due to the implementation of centralized procurement policy in this period; (2) In accordance with the requirements of the accounting standards for business enterprises, the company plans to withdraw the impairment of some fixed assets and long-term equity investments, as well as the estimated liabilities due to investor litigation matters, resulting in the reduction of the net profit attributable to the shareholders of the listed company; (3) In the previous period, the profit and loss obtained from the compensation for house demolition in Keqiao plant area of the company had an impact on the net profit of 179 million yuan, resulting in the achievement of turning losses into profits in 2020, which is not the case in this period.
4、 Other relevant instructions
This performance forecast is the preliminary calculation result of the company’s financial department, which has not been audited by an accounting firm. The specific financial data shall be subject to the data disclosed in the 2021 annual report. Please make careful decisions and pay attention to investment risks.
It is hereby announced.
Zhejiang Yatai Pharmaceutical Co.Ltd(002370) board of directors
January 29, 2022
